论文部分内容阅读
分析应用希罗达联合草酸铂方案(XELOX)和FU/LV联合草酸铂(FOLFOX4)方案治疗的晚期结直肠癌各21例的临床资料。比较XELOX与FOLFOX4方案对于晚期结直肠癌的近期疗效及安全性。结果:XELOX方案的有效率和疾病进展(TTP)分别为47.7%和6.04个月,与FOLFOX4方案相似(52.3%和5.47个月),无显著性差别;XELOX方案的中性粒细胞减少和神经毒性发生率分别为9.5%和0%,显著低于FOLFOX4方案(57.1%和52.4%)(P<0.01);XELOX方案的手足综合症发生率(47.6%)明显高于FOLFOX4方案(14.2%)(P<0.05),但程度较轻,主要为Ⅰ~Ⅱ度。结论:XELOX方案与FOLFOX4方案的疗效相近,但XELOX方案用药更为方便,安全性更好。
Clinical data of 21 patients with advanced colorectal cancer treated with Xelox and FU / LV combined with oxaliplatin (FOLFOX4) regimen were analyzed. To compare the short-term efficacy and safety of XELOX and FOLFOX4 regimens in patients with advanced colorectal cancer. RESULTS: The efficacy and disease progression (TTP) of the XELOX regimen were 47.7% and 6.04 months, respectively, which were similar to the FOLFOX4 regimen (52.3% vs 5.47 months), with no significant difference. The neutropenia and neutropenia The incidence of hand-foot syndrome in XELOX regimen was significantly higher than that in FOLFOX4 regimen (47.6% vs. 14.2%, P <0.01), with rates of 9.5% and 0%, respectively, significantly lower than those of FOLFOX4 (57.1% and 52.4% (P <0.05), but to a lesser extent, mainly Ⅰ ~ Ⅱ degrees. Conclusion: The efficacy of XELOX regimen is similar to FOLFOX4 regimen, but XELOX regimen is more convenient and safe.